Antiangiogenic

Humulone
Catalog No: CFN90541

Humulone, a bone resorption inhibitor, induces apoptosis may via its antioxidative activity in the premyocytic leukemia cell line HL-60 between 1 and 100 micrograms/ml. Humulone is also a potent angiogenic inhibitor, can inhibit cyclooxygenase-2 and may be a novel powerful tool for the therapy of various angiogenic diseases involving solid tumor growth and metastasis. Humulone also has antioxidant, antispasmodic, antiviral and antibacterial activities.

RA-V
Catalog No: CFN92605

RA-V is an potential anti-angiogenic agent, exhibits anti-angiogenic activities in HUVEC and HMEC-1 cell lines with changes in function of these endothelial cells. RA-V also has anti-cancer activity, is a potential anti-metastatic agent in breast cancer, and likely acts via PI3K/AKT and NF-κB signaling pathways in both ER-positive and ER-negative breast cancer cells.

Rhapontigenin
Catalog No: CFN92607

Rhapontigenin has antioxidative, antihyperlipidemic, antifungal and anticancer activities. Rhapontigenin inhibits HIF-1α accumulation and angiogenesis in PC-3 prostate cancer cells, suppresses breast cancer cell migration and invasion, which is involved in inhibiting the PI3K-dependent Rac1 signaling pathway. Rhapontigenin exhibits dose-dependent inhibition of tyrosinase activity and melanin synthesis in B16F10 melanoma cells.

Shikonine
Catalog No: CFN92622

Shikonin(Shikonine), a potent and specific Pyruvate kinase M2 (PKM2) inhibitor, has antibacterial, antitumor, and anti-inflammatory effects, it provides neuroprotection by reducing the release of various proinflammatory molecules from activated microglia. Shikonin can inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice.

Marmesin
Catalog No: CFN92712

Marmesin has hepatoprotective potential; it also has cytotoxic with a 50% lethal dose of less than 0.5 micrograms/ml, is not as mutagenic or potentially carcinogenic as are AFB1, imperatorin, or MOP with BL activation.